Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can telehealth bring HIV prevention to rural drug users?

NCT ID NCT06845774

Prevention Sponsor: Hilary L Surratt, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether offering HIV prevention medication (PrEP) through telehealth visits at local health departments helps more people who inject drugs start and stay on PrEP compared to standard education and referrals. Eighty participants in rural Appalachia will be randomly assigned to either the telehealth program or standard care. The goal is to see if removing travel and provider barriers can increase PrEP use in this underserved group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TelePrEP (telehealth-based PrEP care)
What this could lead to
If successful, this approach could make HIV prevention more accessible for people who inject drugs in rural areas, reducing new infections.
What could go wrong
This is a small pilot study with only 80 participants, so results may not apply broadly. Telehealth may not overcome all barriers to PrEP adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * be at least 18 years of age * report at least one occasion of injection drug use in the past month * report an indication for PrEP in the past six months consistent with CDC guidelines for PrEP care * be a documented client of the county health department-based SSP at the time of study entry * express willingness to participate in a multi-session intervention and follow-up Exclusion Criteria: * HIV-positive status * current PrEP care.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV prevention are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV prevention

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.